BIN1 (Bridging Integrator 1) is a ubiquitously expressed protein belonging to the BAR (Bin-Amphiphysin-Rvs) domain-containing family, which plays critical roles in membrane remodeling, endocytosis, and cytoskeleton regulation. It is involved in diverse cellular processes, including vesicle trafficking, apoptosis, and cell differentiation. BIN1 has gained significant attention due to its association with multiple diseases. In cancer, BIN1 acts as a tumor suppressor in certain contexts but may exhibit oncogenic properties in others, depending on isoform expression and cellular context. Notably, BIN1 is a major genetic risk factor for late-onset Alzheimer’s disease, where it influences tau pathology and amyloid-β metabolism. It also links to cardiovascular diseases, particularly cardiac arrhythmias and myopathies, through its role in T-tubule formation in cardiomyocytes.
BIN1 antibodies are essential tools for studying its expression, localization, and interactions. Multiple isoforms generated by alternative splicing require isoform-specific antibodies for accurate detection. These antibodies enable applications such as Western blotting, immunofluorescence, immunoprecipitation, and immunohistochemistry, helping researchers map BIN1's dynamic roles in health and disease. Additionally, they aid in investigating post-translational modifications (e.g., phosphorylation) that regulate BIN1 function. Validating antibody specificity is crucial due to BIN1's structural homology with other BAR proteins. High-quality BIN1 antibodies are vital for advancing research into its dual roles in neurodegeneration, cancer progression, and cardiac dysfunction, as well as its potential as a therapeutic target or diagnostic biomarker.